Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer
Yanjun Jiang, Polina Iakova, Jingling Jin, Emily Sullivan, Vladislav Sharin, Il‐Hwa Hong, Sayee Anakk, Angela Mayor, Gretchen Darlington, Milton Finegold, David Moore, Nikolai A. Timchenko – 21 November 2012 – One of the early events in the development of liver cancer is a neutralization of tumor suppressor proteins Rb, p53, hepatocyte nuclear factor 4α (HNF4α), and CCAAT/enhancer binding protein (C/EBP) α. The elimination of these proteins is mediated by a small subunit of proteasome, gankyrin, which is activated by cancer.